Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Carl Gordon purchased 1,000,000 shares of Scribe Therapeutics stock in a transaction dated Monday, July 27th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $15,000,000.00. Following the completion of the acquisition, the director owned 1,348,825 shares of the company’s stock, valued at approximately $20,232,375. This trade represents a 286.68% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Scribe Therapeutics Stock Performance
Shares of NASDAQ SCTX traded up $0.30 during mid-day trading on Wednesday, reaching $18.36. The company had a trading volume of 325,049 shares, compared to its average volume of 390,915. Scribe Therapeutics Inc. has a 52 week low of $17.31 and a 52 week high of $25.49.
Further Reading
- Five stocks we like better than Scribe Therapeutics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
